Stopping long-term anti-HER2 therapy in stable metastatic breast cancer
Part of Cancer, Skin clinical trials.
This study asks whether some people with HER2-positive metastatic breast cancer who have been stable for a long time can safely stop their ongoing (maintenance) anti-HER2 treatment. It also uses blood testing and close imaging follow-up to watch for early signs that treatment needs to restart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive metastatic (Stage IV) breast cancer.
- Your scans show complete remission and are stable, including your bone scans, on recent CT/PET/PET-CT.
- You have been on the same (or current) anti-HER2 treatment continuously for at least 36 months.
- Your tumor tissue sample (biopsy) is available for study review.
- Your blood test (Signatera) shows no ctDNA markers (ctDNA-negative).
- You are willing to stop maintenance anti-HER2 treatment and return often for close monitoring.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with advanced HER2-positive breast cancer whose tumors have completely disappeared after recent treatment. It tests whether taking a break from treatment is safe when a special blood test (ctDNA-MRD) shows no trace of cancer remaining.
This trial tests whether it's safe to reduce or stop some cancer treatments for people whose advanced HER2-positive breast cancer has been well-controlled for at least 2 years and has no detectable cancer cells in blood tests.
This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).
This study looks at what happens when people with advanced breast cancer switch to a new treatment after their cancer becomes resistant to targeted therapies like CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd. Researchers want to understand which next treatments work best in real life.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
This trial looks at what happens when women with advanced hormone-positive, HER2-negative breast cancer stop taking a CDK4/6 inhibitor after at least a year of successful treatment. The goal is to see if it's safe to take a break from the CDK4/6 inhibitor while continuing hormone therapy alone.
Hear when a new HER2-positive Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.